Tanjim Hasan Tamim/iStock via Getty Images Cabaletta Bio (NASDAQ:CABA) fast making headway with its lead asset CABA-201 for the treatment of patients with autoimmune disorders. This is a CD-19 CAR-T therapy being used for the treatment of patients with lupus nephritis [SLE of the kidney] and non-renal SLE as well. What makes this company unique would be its approach of attaching a 4-1BB co-stimulatory domain to the drug to enhance efficacy. The main form of the technology is known as Chimeric Antigen Re ...

2019 Employee Stock Purchase Plan 20 In December 2021, we entered into a Licence and Supply agreement, or LSA, with Oxford Biomedica (UK) Limited, or Oxford, wherein the LSA grants us a non-exclusive license to Oxford's LentiVector® platform for its application in our DSG3-CAART program and puts in place a multi-year vector supply agreement. Under the terms of the agreement, we were required to pay Oxford an upfront fee, as well as costs associated with initial vector manufacturing activities for a total co ...

Not applicable. The CARTA Services Agreement is scheduled to expire on the later of February 9, 2026 or completion of all research and development projects, and unless the CARTA Services Agreement is amended, Penn will not be obligated to provide any further services under the CARTA Services Agreement after that time. In addition, Penn has the right to terminate the CARTA Services Agreement in whole at any time with 180 days' notice. From time to time, we may enter into further addenda to the CARTA Services ...

1 • the potential advantages of our proprietary Cabaletta Approach for B cell Ablation platform, called our CABA TM platform, and our product candidates; • our ability to obtain funding for our operations, including funding necessary to initiate and complete our DesCAARTes TM trial, our MusCAARTes TMtrial, our planned clinical trial of CABA-201 and our ongoing preclinical studies of other product candidates; • the potential achievement of milestones and receipt of payments under our collaborations; • our ab ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39103 CABALETTA BIO, INC. (Exact name of Registrant as specified in its Charter) Delaware 82-1685768 (State or other jurisdiction of ...

2 Cabaletta Bio° CARTA Strategy | CABA-201 (4-1BB CD19-CAR T) expecting 1H23 IND clearance1 CAART Strategy | DSG3-CAART & MuSK-CAART clinical studies evaluating combination regimens CAART – Chimeric AutoAntibody Receptor T cells; CARTA – Chimeric Antigen Receptor T cells for Autoimmunity; IND – Investigational New Drug; SLE – Systemic lupus erythematosus; RA – Rheumatoid arthritis 5 Chimeric Antigen Receptor T cells for Autoimmunity Fully Human Anti-CD19 Targeting Domain In autoimmune diseases with a limite ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_______________ to _______________ | --- | --- | |-----------------------------------------------------------------------------------------|----------------- ...

Cabaletta Bio° Corporate Presentation SEPTEMBER 2022 © 2022 Cabaletta Bio. All rights reserved. Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (collectively, the "Presentation") has been prepared by Cabaletta Bio, Inc. ("we," "us," "our," ...

Cabaletta Bio° Corporate Presentation AUGUST 2022 © 2022 Cabaletta Bio. All rights reserved. Disclaimer 2 The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (collectively, the "Presentation") has been prepared by Cabaletta Bio, Inc. ("we," "us," "our," " ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Non-accelerated filer ☒ Smaller reporting company ☒ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_______________ to _______________ Commission File Number: 001-39103 CABALETTA BIO, INC. (Exact Name of Regist ...